UK
UK RNA Interference Therapeutics Market Industry Trends and Forecast to 2034: Segmented by (Molecule, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
UK · 2024–2034 · estimates
Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Germany at $212.2 Mn.
Russia at 19.8% a year.Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$520.4 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $128.4 Mn | — | — |
| 2025 (base) | $151.5 Mn | +$23.1 Mn | — |
| 2026 (forecast) | $178.8 Mn | +$27.3 Mn | +18% |
| 2027 (forecast) | $210.9 Mn | +$32.2 Mn | +39.2% |
| 2028 (forecast) | $248.9 Mn | +$38.0 Mn | +64.3% |
| 2029 (forecast) | $293.7 Mn | +$44.8 Mn | +93.9% |
| 2030 (forecast) | $346.6 Mn | +$52.9 Mn | +128.8% |
| 2031 (forecast) | $409.0 Mn | +$62.4 Mn | +170% |
| 2032 (forecast) | $482.6 Mn | +$73.6 Mn | +218.5% |
| 2033 (forecast) | $569.4 Mn | +$86.9 Mn | +275.9% |
| 2034 (forecast) | $671.9 Mn | +$102.5 Mn | +343.5% |
Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
US
$2.04 Bn
China
$461.5 Mn
Canada
$445.4 Mn
Japan
$320.4 Mn
Germany
$212.2 Mn
UK (this report)
$151.5 Mn
France
$149.6 Mn
Brazil
$153.7 Mn
Italy
$135.7 Mn
Ecuador
$123.5 Mn
Saudi Arabia
$112.4 Mn
Spain
$105.4 Mn
India
$110.4 Mn
Mexico
$74.7 Mn
Australia
$63.3 Mn
Russia
$59.8 Mn
New Zealand
$59.8 Mn
South Africa
$37.5 Mn
UAE
$25.3 Mn
Egypt
$16.0 Mn
Philippines
$14.3 Mn
Malaysia
$10.5 Mn
Hong Kong
$9.0 Mn
Singapore
$8.0 Mn
Thailand
$6.5 Mn
Kenya
$4.4 Mn
RNA interference therapeutics use small RNA molecules to switch off disease-causing genes, used in rare, heart and liver diseases.
Key segments of the RNA Interference Therapeutics market include molecule (siRNA, Antisense Oligonucleotides and microRNA) and indication (Rare Genetic Diseases, Cardiovascular and Liver Diseases).
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the RNA Interference Therapeutics market.
Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the RNA Interference Therapeutics market.
Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the RNA Interference Therapeutics market. Payers are still working out how to pay for one-time cures.
The RNA Interference Therapeutics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for RNA Interference Therapeutics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in UK.
What doctors and scientists are doing in RNA Interference Therapeutics right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
UK · 2 shared keywords
UK · 1 shared keyword
UK · 1 shared keyword
UK · 1 shared keyword
UK · 1 shared keyword
UK · 1 shared keyword
Medical Devices · UK
Digital Health · UK
Healthcare Services · UK
Healthcare Services · UK
Medical Devices · UK
Healthcare Services · UK